NASDAQ:JSPRW Jasper Therapeutics (JSPRW) Stock Price, News & Analysis $0.0002 0.00 (0.00%) As of 09/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsNews and TrendsSEC Filings About Jasper Therapeutics Stock (NASDAQ:JSPRW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jasper Therapeutics alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range$0.0002▼$0.014452-Week Range$0.00▼$0.15VolumeN/AAverage Volume32,893 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases involving hematopoietic stem cells, including conditions treated with stem cell transplantation and gene therapy. The company’s research is centered on antibody-based medicines designed to improve the safety and effectiveness of conditioning regimens used before transplantation. Jasper’s lead product candidate is briquilimab, an investigational monoclonal antibody that targets CD117, a protein found on hematopoietic stem cells. By temporarily reducing these cells, briquilimab is intended to help create space in the bone marrow for transplanted or genetically modified cells while potentially reducing the toxicity associated with conventional chemotherapy-based conditioning. The company has evaluated briquilimab in clinical programs involving rare inherited disorders, hematologic malignancies and other diseases that may benefit from targeted stem-cell depletion. Jasper Therapeutics is headquartered in the United States and conducts its development activities through research collaborations and clinical studies. Its securities include common stock traded under the symbol JSPR and publicly traded warrants under the symbol JSPRW.AI Generated. May Contain Errors. Read More Receive JSPRW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JSPRW Stock News HeadlinesJasper Therapeutics consensus price target increased 19.86% to $8.92October 2, 2026 | msn.comJasper Therapeutics, Inc.(NasdaqCM:JSPR) added to NASDAQ Composite IndexSeptember 19, 2026 | marketscreener.comMI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 14 at 1:00 AM | Weiss Ratings (Ad)Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Key Regulatory and Clinical AppointmentsSeptember 16, 2026 | finanznachrichten.deJasper Therapeutics Appoints Regulatory, Clinical Executives For Pipeline Development; Stock UpSeptember 16, 2026 | rttnews.comJSPRW - Jasper Therapeutics, Inc. WT EXP 092426August 27, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Aptevo Therapeutics (APVO) and Jasper Therapeutics (JSPR)August 20, 2026 | theglobeandmail.comJasper Therapeutics beats Q2 expectations but shares fall after resultsAugust 17, 2026 | finance.yahoo.comSee More Headlines JSPRW Stock Analysis - Frequently Asked Questions How have JSPRW shares performed this year? Jasper Therapeutics' stock was trading at $0.0401 at the beginning of 2026. Since then, JSPRW stock has decreased by 99.5% and is now trading at $0.0002. Company Calendar Today10/14/2026Next Earnings (Estimated)11/05/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 JSPRW's financial health is in the Red zone, according to TradeSmith. JSPRW has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:JSPRW CIK1788028 Webjaspertherapeutics.com Phone650-549-1400FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:JSPRW) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
